Table 1.
Sample characteristics
| Ctx+ | Ctx− | Significance | |
|---|---|---|---|
| Demographics | N = 22 | N = 22 | |
| Age at baseline (years, mean (SD)) | 49.68 (8.0) | 52.68 (9.3) | 0.256 |
| Race (%, Caucasian) | 77.3 | 86.4 | 0.349 |
| Education (years, mean (SD)) | 15.59 (2.8) | 15.27 (2.4) | 0.684 |
| Less than high school (<12 years, %) | 4.5 | 4.5 | – |
| High school (12 years, %) | 9.1 | 9.1 | – |
| Some college (13–15 years, %) | 36.4 | 27.3 | – |
| Four-year college (16 years, %) | 18.2 | 27.3 | – |
| More than four-year college (>16 years, %) | 31.8 | 27.3 | – |
| Cancer and cancer treatment | |||
| Stage of breast cancer at diagnosis (%, stages 0–3) | |||
| Stage 0 | 0.0 | 18.2 | |
| Stage 1 | 50.0 | 68.2 | 0.002 c |
| Stage 2 | 40.9 | 13.6 | |
| Stage 3 | 9.1 | 0.0 | |
| Chemotherapy | |||
| Adjuvant (%) | 68.2 | 0.0 | – |
| Neo-adjuvant (%) | 31.8 | 0.0 | – |
| Received chemotherapy (any type, %) | 100.0 | 0.0 | – |
| Received a single neurotoxic agent during treatment (%) | 95.5 | 0.0 | – |
| Received two or more neurotoxic agents during treatment (%) | 31.7 | 0.0 | – |
| Type of chemotherapy received | |||
| Taxane (%) | 95.5 | 0.0 | – |
| Docetaxel (%) | 54.5 | 0.0 | – |
| Paclitaxel (%) | 40.9 | 0.0 | – |
| Platinating agent (%) | 22.7 | 0.0 | – |
| Carboplatin (%) | 22.7 | 0.0 | – |
| Received both taxane and platinum (%) | 22.7 | 0.0 | – |
| Total exposure to neurotoxic chemotherapy (mg/m2, mean (SD)) | 1757.1 (1967.3) | 0.0 | – |
| Total exposure to a taxane (mg/m2, mean (SD)) | 911.1 (491.8) | 0.0 | – |
| Amount of paclitaxel (mg/m2) | 452.5 (727.6) | 0.0 | – |
| Amount of docetaxel (mg/m2) | 388.7 (376.9) | 0.0 | – |
| Amount of carboplatin (mg/m2) | 958.1 (1828.9) | 0.0 | |
| Radiotherapy | |||
| Received radiotherapy during treatment (%) | 81.8 | 59.1 | 0.099 |
| Amount of radiation per fraction (Gy, mean (SD)) | 2.07 (0.96) | 1.93 (0.80) | 0.717 |
| Hormonal therapies | |||
| Aromatase inhibitor (AI; %) | 27.2 | 45.5 | 0.510b |
| Selective estrogen receptor modulators (SERMs; %) | 22.7 | 36.4 | 0.210a |
| Biologic agents | |||
| Trastuzamab (%) | 22.7 | 0.0 | 0.048 b |
| Other agents associated with painful and/or CIPN-like symptoms | |||
| Biphosphanate (%) | 13.6 | 0.0 | 0.233b |
BC breast cancer, SD standard deviation, Ctx+ women with breast cancer treated with surgery and/or radiation and chemotherapy, Ctx− women with breast cancer treated with surgery and/or radiation but no chemotherapy
In some cases, totals in a particular category do not equal 100.0 % because participants may have received more than one agent during treatment. Differences between quantitative variables were tested using independent sample t-tests, α = 0.05. Note Values in italics are significant at α= 0.05
aDifferences between categorical variables with adequate cell counts were tested with Pearson’s chi-squared tests (two-sided), α = 0.05
bDifferences between categorical variables with inadequate cell counts (i.e., <5 observations) were tested with Fisher’s exact test (two-sided), α = 0.05
cDifferences between categorical variables with inadequate cell counts (i.e., <5 observations) where order mattered were tested with Mantel-Hanzel chi-squared tests (two-sided), α = 0.05